Medical knowledge of glioblastoma multiforme (GBM), the deadliest form of brain cancer, has grown exponentially, but has not resulted in marked improvements in treatment for patients. Addressing this is GBM AGILE (GBM Adaptive Global Innovative Learning Environment), a global medical and scientific coalition that is the first platform trial for…...
In recognition of Esophageal Cancer Awareness Month, this National Foundation for Cancer Research post offers a look at a significant diagnostic advancement for a risk factor associated with the terrible disease. A new test for Barrett’s esophagus, a precancerous forerunner of the much deadlier esophageal adenocarcinoma, is in clinical trials…...
Led by Dr. Gunnel Halldén of Queen Mary University in London, a team of scientists modified a common flu virus to successfully inhibit the growth of pancreatic cancer. The new technique could potentially become a promising new treatment for patients with the aggressive disease, and could be combined with existing…...
President Bill Clinton declared March Colorectal Cancer Awareness Month in 2000, highlighting a disease that represents eight percent of all new cancers diagnosed yearly and, out of the estimated 135,430 people who developed it just last year, caused an estimated 50,260 deaths in the United States alone. As outlined in…...
Although stomach (AKA gastric) cancer is the third deadliest cancer in the world, claiming an estimated 10,960 lives in the United States alone in 2017, it remains one of the more difficult cancers to notice and detect. Indeed, more than two-thirds of patients are diagnosed only after the disease is…...
FOR IMMEDIATE RELEASE: February 15, 2018 CONTACT: Bradley Gillenwater, Senior Director for Global Programs & Communications E-mail: bgillenwater@nfcr.org First Occasion for Award to Recognize Extraordinary Contributions in Cancer Prevention, Role of Vaccines BETHESDA, MD – The National Foundation for Cancer Research (NFCR) announced today that the 2018 Szent-Györgyi Prize…...
CLEVELAND, OH — Two studies conducted by the Cleveland Clinic revealed how a testosterone-related genetic abnormality can help predict individual patient responses to specific prostate cancer therapies. The studies, published in the October 12 issue of JAMA Oncology, suggest that men who inherit this variant would benefit from a personalized…...
Szent-Györgyi Prize Winners: Then & Now The Szent-Györgyi Prize was established in honor of Nobel laureate Dr. Albert Szent-Györgyi, co-founder of NFCR, to recognize outstanding scientific achievement in the war against cancer. Ten years later, “ASG Winners: Then & Now” looks at these winners, their extraordinary contributions and how their discoveries have made possible new…...
Free Cancer Screening Guidelines
National Foundation for Cancer Research(NFCR) is a 501(c)(3) tax-exempt nonprofit organization.
Tax ID #: 04-2531031
5515 Security Lane, Suite 1105 Rockville, MD 20852
